



HAL
open science

Intranasal inoculations of naked or PLGA-PEI nanovectored DNA vaccine induce systemic and mucosal antibodies in pigs: A feasibility study

Laurent Souci, Hervé Jaunet, Gérald Le Diguerher, Jean-Marie Guionnet, Véronique Béven, Frédéric Paboeuf, Tristan Montier, Daniel Dory

► To cite this version:

Laurent Souci, Hervé Jaunet, Gérald Le Diguerher, Jean-Marie Guionnet, Véronique Béven, et al.. Intranasal inoculations of naked or PLGA-PEI nanovectored DNA vaccine induce systemic and mucosal antibodies in pigs: A feasibility study. *Research in Veterinary Science*, 2020, 132, pp.194-201. 10.1016/j.rvsc.2020.06.018 . hal-03093878

HAL Id: hal-03093878

<https://hal.inrae.fr/hal-03093878>

Submitted on 15 Jul 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1

2

3 **Intranasal inoculations of naked or PLGA-PEI nanovectored**
4 **DNA vaccine induce systemic and mucosal antibodies in pigs: a**
5 **feasibility study**

6

7

8 **Laurent Souci** ^{1,a}, **Hervé Jaunet** ², **Gérald Le Digerher** ³, **Jean-Marie Guionnet** ³,
9 **Véronique Béven** ¹, **Frédéric Paboeuf** ³, **Tristan Montier** ⁴, **Daniel Dory** ^{1,*}

10

11 ¹ French Agency for Food, Environmental and Occupational Health & Safety (ANSES),
12 Viral Genetics and Biosafety Unit, Ploufragan, France

13 ² ZOOPOLE Development, Ploufragan, France

14 ³ French Agency for Food, Environmental and Occupational Health & Safety (ANSES),
15 Pig Production and Experimental Unit, Ploufragan, France

16 ⁴ SynNanoVect platform - UMR INSERM 1078, University of Brest, Brest, France

17

18 * Corresponding author: Daniel Dory. ANSES, Ploufragan/Plouzané Laboratory, Viral
19 Genetics and Biosafety Unit, BP 53, 22440 Ploufragan, France.

20 Tel.: +33 2 96 01 64 42; Fax: +33 2 96 01 62 83.

21 E-mail: daniel.dory@anses.fr

22

23 ^a Present address: INRAE, Biology of Avian Viruses team, Nouzilly, France

24

25 **Abstract:**

26 Mucosa are the routes of entry of most pathogens into animals' organisms. Reducing the
27 important global burden of mucosal infectious diseases in livestock animals is required in the
28 field of veterinary public health. For veterinary respiratory pathogens, one possible strategy
29 is the development of intranasal (IN) DNA vaccination. The aim of this study was to assess
30 the feasibility of IN DNA vaccination in pigs, an important species in livestock production
31 industry, and a source of zoonotic diseases. To achieve this goal, we used a DNA vaccine
32 against pseudorabies virus (PrV) encoding the immunogenic glycoprotein B (pcDNA3-gB
33 plasmid). When pigs were inoculated with the naked DNA vaccine through the IN route,
34 PrV-specific IgG and IgA type antibodies were detected in porcine sera. Interestingly,
35 mucosal salivary IgA antibodies against PrV were also detected, at similar levels to those
36 measured following intramuscular injection (positive controls). Furthermore, the IN delivery
37 of pcDNA3-gB combined with PLGA-PEI nanoparticles resulted in similar levels of
38 antibodies but was associated with an increase in the duration of detection of mucosal IgA for
39 2 out of 3 pigs. Our results suggest that there is room to improve the efficacy of IN DNA
40 vaccination in pigs through optimization of IN inoculations, for example by using
41 nanoparticles such as PLGA-PEI. Further studies will be dedicated to optimizing and testing
42 the protective potential of IN DNA vaccination procedures against PrV.

43

44 **Keywords:** DNA vaccination; swine; intranasal; antibodies; salivary IgA

45

46

1. Introduction

47 Respiratory pathogens of livestock animals are responsible for high economic losses for
48 farms due to high morbidity and sometimes lethal respiratory diseases. In some rare cases,

49 animal pathogens can be transmitted and emerge in humans, as exemplified with the 2009
50 H1N1 influenza pandemic of swine origin (Hass et al., 2011). It is therefore necessary to
51 develop strategies to control animal infections, and vaccination represents one of the most
52 powerful tools available. Vaccines administered via the systemic route are often effective in
53 inducing broad and heterologous protective immunity, but there are exceptions. In these
54 cases, like for vaccination against swine influenza or porcine reproductive and respiratory
55 syndrome (Dhakal and Renukaradhya, 2019), mucosal vaccination may be beneficial.
56 Because respiratory pathogens enter the body through the respiratory mucosa, induction of
57 mucosal protective immune responses may limit entry of the pathogens and associated
58 infection (Kraehenbuhl and Neutra, 2013). Mucosae are located in various cavities of the
59 body, at the interface between the external and internal environments (*e.g.* respiratory or
60 gastrointestinal tracts). They contribute to essential functions such as respiration, nutrition,
61 and reproduction, while playing a protective role by preventing the physical entry of
62 pathogens (Liebler-Tenorio and Pabst, 2006), and by mobilizing the innate and specific local
63 immune systems (Lawson et al., 2011; Liebler-Tenorio and Pabst, 2006; Lycke, 2012; Pabst,
64 2012). Moreover, a key part of mucosal immunity is mucosa-associated lymphoid tissues
65 (MALTs), that are functionally interconnected despite being anatomically separated, thus
66 allowing protection through IgA secretion can reach a broad range of distant mucosal
67 surfaces (McGhee and Fujihashi, 2012).

68 Most mucosal vaccination strategies involve the oral or nasal routes. Most mucosal
69 vaccines consist of attenuated pathogens, with no or very low virulence (Lycke, 2012; Pavot
70 et al., 2012) that mimic as much as possible the wild-type pathogens they are derived from
71 and can therefore enter the organism through the mucosa. Because these viruses remain alive,
72 reversion to virulence or interactions with other pathogens present at the time of inoculation
73 have been reported (Eclercy et al., 2019; Liu et al., 2018). Therefore, as a safety measure, it is
74 recommended to develop subunit vaccines. For example, vaccine antigens can be inserted

75 into viral or bacterial vectors, be administered as recombinant proteins (Wang et al., 2015) or
76 as DNA vaccines (Farris et al., 2016; Oh et al., 2001). Among those, the DNA vaccine
77 strategy presents many advantages, the main one being its simplicity. DNA vaccination
78 consists in inoculating plasmid DNA encoding the vaccine antigen. These antigens are then
79 produced in the vaccinated animals, inducing humoral and cellular immune responses
80 (Dufour, 2001). In addition, DNA vaccines are non-infectious, easy to develop and to
81 produce in high quantities, and they induce an immune response different from that of natural
82 infection allowing differentiation of infected and vaccinated animals (DIVA). DNA
83 vaccination has successfully been achieved in the veterinary field and several vaccines are
84 available on the market (Clynav[®], West Nile Innovator[®], Apex-IHN[®] and Oncept[®] vaccines)
85 (Dalmo, 2018). For intranasal (IN) DNA vaccination, the vaccine is either be inoculated in its
86 naked form (Gomes et al., 2007) or combined with vectors (liposomal or
87 nano/microparticulate structures) that serve as mucosal delivery systems (Csaba et al., 2009).
88 It was previously shown in rodents that such nanovectors can protect the vaccine DNA from
89 mucosal degradation and favor interaction with mucosal cells, antigen-presenting cells
90 (APCs) or inductive sites of MALTs (Kraehenbuhl and Neutra, 2013). The two most
91 common biopolymers, described for IN DNA vaccination purposes, are chitosan (Khatri et
92 al., 2008) and poly(lactic-co-glycolic) acid (PLGA) (Du et al., 2015). In particular, PLGA
93 has been optimized for a more efficient delivery and internalization of the DNA vaccine by
94 mucosal surfaces (*e.g.* nasal cavity). For example, the combination of polyethylenimine
95 (PEI) with PLGA enhances electrostatic interactions of PLGA with DNA plasmids (thanks to
96 cationic nature of the PEI) and promotes its interaction with mucosal cells, and no cell
97 cytotoxicity was reported (Shau et al., 2012). However, it is important to point out that the
98 vast majority of IN DNA vaccine studies were performed using mice or guinea pigs (Ai et al.,
99 2013; Du et al., 2015; Iqbal et al., 2003; Khatri et al., 2008; Nanda et al., 2014). Given the
100 importance of respiratory pathogens in the veterinary field, and associated risks for zoonotic

101 diseases, there is a strong need to conduct new studies to determine the efficacy of IN DNA
102 vaccination for livestock animals such as pigs.

103 Given that the respiratory tract is the most common route of viral entry, IN DNA
104 vaccination strategies represent a novel and promising vaccination strategy. The
105 pseudorabies virus (PrV) that uses nasal cells as a route of entry into the pig body (Babic et
106 al., 1994) is an ideal viral model to test IN DNA vaccination in pigs. Also, intramuscular
107 DNA vaccination is effective and can be used as positive control (Dory et al., 2005; Gerdts et
108 al., 1997). Among the glycoproteins encoded by the PrV DNA vaccine, the glycoprotein B
109 (gB) is of particular interest because it is highly immunogenic (Dory et al., 2009) and could
110 be used to validate new DNA vaccine strategies. This protein has previously been used in our
111 laboratory to evaluate the potential of electroporation for porcine DNA vaccination (Le
112 Moigne et al., 2012).

113 In the present study, the plasmid encoding PrV-gB (pcDNA3-gB) associated with a
114 plasmid pcDNA3-GM-CSF encoding granulocyte macrophage colony stimulating factor
115 (GM-CSF used as an adjuvant (Somasundaram et al., 1999)) was administered intranasally in
116 its naked form or associated with the nanovector PLGA-PEI. Naked DNA IN inoculation
117 resulted in mucosal salivary IgA antibodies production. Furthermore, the vectored DNA
118 vaccine appeared to extend the duration of IgA production compared to naked DNA alone.
119 These promising results justify further studies to optimize IN DNA vaccination in pigs to
120 prevent infectious respiratory diseases.

121

122 **2. Materials and Methods**

123 **2.1 Plasmids**

124 Plasmids pcDNA3-gB (encoding PrV-gB) (Dory et al., 2009), pcDNA3-GM-CSF
125 (encoding granulocyte macrophage colony stimulating factor) (Somasundaram et al., 1999),
126 and pTG11033 (encoding luciferase) (Lindberg et al., 2015) were produced in *E. coli* and

127 purified using a Maxiprep plus endotoxin-free DNA extraction kit (Macherey-Nagel,
128 Germany), according to the manufacturer's instructions. The plasmids were resuspended in
129 endotoxin-free tris-EDTA buffer. Plasmid concentrations and purities were assessed
130 spectrophotometrically by measuring OD ratios at 260 nm/280 nm, and 260 nm/230 nm,
131 respectively (Plate reader infinite 200 Pro, TECAN Ltd, Switzerland).

132

133

134 **2.2 Preparation of plasmid-PLGA-PEI nanoparticles**

135 PLGA-PEI nanoparticles were purchased from NanoVex Biotechnologies (Spain). The
136 sizes of the particles were 200 ± 12 nm and the zeta potentials were 38.9 ± 0.4 mV.
137 plasmid-PLGA-PEI nanoparticles were obtained by the adsorption of plasmid DNA onto
138 PLGA-PEI surfaces, as previously described (Shau et al., 2012). Briefly, plasmid DNA and
139 PLGA-PEI were diluted into ultrapure water and mixed at a weight DNA/weight PEI ratio of
140 12, vortexed for 30 sec and incubated for one hour at room temperature (RT). Freshly
141 prepared nanoparticles were inoculated or studied *in vitro* within hours.

142

143

144 **2.3 Assessment of humoral immune responses after IM injection or IN inoculation of a** 145 **naked PrV-gB-based DNA vaccine**

146 All the experimental protocols described in this paper were approved by the ethics
147 committee for animal experimentation of ANSES/National Veterinary School of
148 Alfort/University of Paris-Est Créteil (France) (Notice number 10/07/18-3), and by the
149 French Ministry of Research under reference 15614-201806210855647_v2.

150 Two groups of 8–9-week-old specific pathogen-free (SPF) pigs were inoculated three
151 times at 10-day intervals (**Fig. 1A**). They weighed 24.5 ± 2.9 kg at the time of the first
152 inoculation. Pigs in group #1 (n=3 pigs) were injected with 4 mL of the DNA vaccine

153 composed of 400 µg of pcDNA3-gB and 100 µg of pcDNA3-GM-CSF by the IM route in the
154 neck muscle. pcDNA3-GM-CSF was used as an adjuvant, as previously described
155 (Somasundaram et al., 1999). Pigs in group #2 (n=3 pigs) were inoculated with the same
156 DNA vaccine by the IN route (2 mL in each nostril) using an MAD100 NasalTM Intranasal
157 Mucosal Atomization Device (Teleflex Medical, Wayne, USA). Non-inoculated control pigs
158 made up an additional group, group #3 (n=2 pigs). All pigs were observed daily to detect any
159 adverse reactions. Body temperatures were measured daily and pigs were weighed weekly.
160 Blood sera were collected on days 0, 10, 20, 29 and 37 post-inoculation (pi). Salivary
161 samples were collected on days 29 and 37 pi. On day 38 pi, pigs were anesthetized with an
162 auricular intravenous injection of thiopental (1 g/50 kg body weight) and euthanized. All the
163 organs and the snout of each pig were observed during the autopsies to detect any problem
164 linked to inoculations.

165

166 **2.4 Assessment of humoral immune responses after IN inoculation of naked or** 167 **nanovectored PrV-gB-based DNA vaccines**

168 Four groups of 7–8-week-old SPF pigs were inoculated three times at 10-day intervals
169 (**Fig. 1B**). They weighed 25.9 ± 5.7 kg at the time of the first inoculation. Three groups of
170 three pigs were inoculated by the IN route using an MAD100 NasalTM Intranasal Mucosal
171 Atomization Device (Teleflex Medical, Wayne, USA) with 300 µg of pcDNA3-gB + 100 µg
172 of pcDNA3-GM-CSF (2 mL corresponding to half of the DNA vaccine in each nostril). Pigs
173 in groups #1 and #2 were inoculated with naked pcDNA3-gB and PLGA-PEI-pcDNA3-gB,
174 respectively. One control pig (group #3) was injected three times at the same time points with
175 the same naked DNA vaccine (4 mL in total) by the IM route. Finally, an additional group of
176 four non-inoculated pigs served as negative controls (group #4). Clinical observations and
177 euthanasia were performed as described above, except that euthanasia was performed on day
178 50 pi. Blood sera were collected the day before the first inoculation and on days 9, 20, 27, 37,

179 44 and 50 pi. Salivary samples were collected the day before the first inoculation and on days
180 10, 20, 30, 37 and 44 pi.

181

182 **2.5 Determination of serum anti-PrV IgG and IgA antibody titers**

183 An indirect ELISA for the determination of serum anti-PrV-specific IgG and IgA
184 antibody titers was adapted from the protocol previously described (Le Moigne et al., 2012).
185 Briefly, maxiSorp 96-well plates (Nunc, ThermoFisher, USA) were coated overnight with
186 1.5 µg/well of PrV glycoproteins diluted in 100 µL of 0.05 M carbonate buffer
187 (Sigma-Aldrich, USA) at 4°C. The plates were washed twice with phosphate buffered saline
188 (PBS) buffer pH 7.4 containing 0.05% tween 20 (PBS-T, Sigma-Aldrich, USA) prior to
189 being blocked with 300 µL/well of blocking buffer [1% BSA (Eurobio, France) in PBS-T]
190 for two hours at 37°C. After two washes with PBS-T, the plates were incubated for 1 h at
191 37°C with 100 µL/well of two-fold serial diluted serum samples in PBS-T. Each serum
192 sample was analyzed in triplicate. After three washes, the plates were incubated for 1 h at
193 37°C with 100 µL/well of 1:20,000 diluted horseradish peroxidase (HRP)-conjugated goat
194 anti-pig IgG (H/L) (Bio-Rad, USA) or 1:100,000 diluted HRP-conjugated goat anti-pig IgA
195 AAI40P antibody (Bio-Rad, USA) for IgG or IgA determinations, respectively. These
196 antibodies were diluted in 1% BSA/PBS-T. Finally, after three washes, 100 µL/well of
197 tetramethylene benzidine (TMB) substrate (Pierce TMB substrate kit, ThermoFischer
198 Scientific, USA) was added to the plates for 5 or 10 min for IgG or IgA determinations,
199 respectively. The reactions were stopped by adding 100 µL/well of 2 M sulphuric acid
200 (H₂SO₄, Sigma-Aldrich, USA). The plates were shaken for 1 min and the absorbance at 450
201 nm of each well was read on an Infinite 200 Pro plate reader (TECAN Ltd, Switzerland).
202 Antibody titers were expressed as the highest dilution giving an OD value higher than the
203 threefold OD of the control sera from the non-vaccinated and non-infected pigs.

204

205 **2.6 Determination of salivary anti-PrV IgA antibody titers**

206 An indirect ELISA was performed on salivary samples in triplicate as described above
207 for the serum samples, with minor modifications. 1:150,000 diluted AAI40P
208 HRP-conjugated goat anti-pig IgA antibody and 15 min of incubation with the
209 TMB-substrate were used.

210

211 **2.7 *In vitro* characterization of the nanovectored plasmids**

212 The plasmids were characterized as previously described, with some modifications
213 (Berchel et al., 2015; Le Gall et al., 2013). Twenty thousand cells/well of human bronchial
214 epithelial cells (HBE-16) were incubated in 96-well plates overnight (37°C, 5% CO₂) with
215 Eagle's minimal essential medium (EMEM) supplemented with 1% penicillin/streptomycin
216 antibiotics, 1% glucosamine (Gibco, ThermoFisher, USA) and 10% fetal bovine serum.
217 Then, the cells were incubated in triplicate for 72 hours with 40 µL/well of either naked
218 pTG11033 plasmid or PLGA-PEI-pTG11033. Controls consisted of EMEM or of PLGA-PEI
219 without DNA. Thereafter, the cultures were assessed for cytotoxic effects and the
220 transfection potential of each DNA or nanovector preparation.

221

222 **2.7.1 Cytotoxic effect evaluation**

223 Each preparation described above was evaluated for cytotoxic effects on cell
224 supernatants using a CytoTox 96[®] Non-Radioactive Cytotoxicity Assay kit, according to the
225 manufacturer's instructions (Promega, USA).

226

227 **2.7.2 Transfection potential evaluation**

228 After removing the remaining culture medium, 75 µL/well of passive lysis buffer (PLB
229 buffer, Promega, USA) were added. Then, 25 µL of each cell lysate were transferred to two
230 separates plates. The first plate (a transparent MaxiSorp 96-well plate, Nunc, Naperville,

231 USA) was used to determine total protein content using a BC Assay kit, according to the
232 manufacturer's instructions (Pierce, ThermoFisher, USA). The other plate (a white
233 MaxiSorpLumiNunc 96-well plate, Nunc, USA) was used to measure luciferase activities
234 using the Promega Firefly Luciferase Assay System (Promega, USA), according to the
235 manufacturer's instructions. An amount of 65 μ L per well of Promega Luciferase Assay
236 Reagent was added. After 2 min incubation at RT in the dark, the luminescence was
237 measured with a luminescence Infinite 200 Pro plate reader (TECAN Ltd, Switzerland), with
238 reading and delay times of one second each. The results were expressed as relative light units
239 (RLUs) per milligram of total proteins.

240

241 **2.8 Statistical analyses**

242 For the *in vitro* experiments, a Mann–Whitney–Wilcoxon (U) test (non-directional
243 test) was used. Comparisons were performed at a limit of significance of 0.05.

244

245 **3. Results**

246 **3.1 PrV-specific systemic and mucosal humoral responses induced after IN inoculation** 247 **of the naked PrV-gB-based DNA vaccine (pig experiment #1)**

248 Two groups of three pigs were inoculated three times at ten-day intervals with a naked
249 pcDNA3-gB-based DNA vaccine either through the IM or IN route, respectively (**Fig. 1A**).
250 A third group of two pigs was not inoculated and served as a control group. None of the DNA
251 inoculated pigs had fever, showed side effects, and they all grew similarly to the
252 non-inoculated animals for the duration of the experiment. At necropsy, no lesions related to
253 the inoculation or injection procedures were observed.

254

255 **3.1.1 Determination of serum anti-PrV IgG and IgA following IM or IN inoculation of** 256 **the naked PrV-gB-based DNA vaccine**

257 In previous studies, we showed that pcDNA3-gB when inoculated intramuscularly
258 induced strong production of systemic anti-PrV IgG antibodies (Dory et al., 2009; Le Moigne
259 et al., 2012). Here, as expected, the three pigs injected with the PrV-gB-based DNA vaccine
260 by the IM route exhibited an elevated serum anti-PrV IgG response that started to be detected
261 on day 20 pi (10 days after the second injection), and the response remained high or increased
262 after the third injection until the end of the pig experiment (**Fig. 2A**). Maximum titers
263 expressed in log₂ base were between 13.5 (pigs #2 and #3) and 15.2 (pig #1). Serum anti-PrV
264 IgA antibodies started to be detected on day 10 pi for pig #1, and on day 20 pi for the other
265 two pigs (**data not shown**). The highest titers were observed on day 29 pi (between 6.3 and
266 7.3 log₂). The two non-inoculated pigs produced no anti-PrV IgG and IgA (**Fig. 2A and data**
267 **not shown**).

268 For the group inoculated by the IN route with the naked PrV-gB-based DNA vaccine,
269 pig #3 produced IgG antibodies against PrV from 20 days pi to the end of the pig experiment
270 (**Fig. 2B**). On day 37 pi, the titer was 9.3 log₂ for this pig. Pig #2 in this group also exhibited
271 an increasing level of PrV-specific serum IgG response, but it started only after the third
272 inoculation (day 29 pi). It reached a titer of 6.3 log₂ at the end of the pig experiment (37 dpi).
273 For the third pig (pig #1), a transient and very low response was observed only on day 29 pi
274 (4.4 log₂). Concerning the induction of systemic anti-PrV IgA, pig #1 elicited such a
275 response from 20 dpi (highest titer of 6.3 log₂ on day 20 pi) (**data not shown**). The other two
276 pigs showed only a slight increase of the titer on day 37 pi (3.1 log₂) (**data not shown**).

277

278 **3.1.2 Determination of anti-PrV sIgA in the saliva of pigs following IM or IN** 279 **inoculation of the naked PrV-gB-based DNA vaccine**

280 Thereafter, the presence of anti-PrV sIgA was determined in pig saliva collected on days
281 29 and 37 pi (**Fig. 3**). No antibodies were detected in the samples from the two
282 non-inoculated pigs. Antibodies were detected in two out of three pigs injected by the IM

283 route with the naked DNA vaccine. The titers of antibodies were 3.4 and 4.3 log₂,
284 respectively. More interestingly, all the pigs inoculated through the IN route with the naked
285 PrV-gB-based DNA vaccine had sIgA titers against PrV at least at the same order of
286 magnitude as those of the pigs injected through the IM route with the same vaccine.
287 Furthermore, pig #2 presented higher titers than those detected in the IM group (titers of 7.3
288 and 6.3 log₂ on days 29 and 37 pi, respectively).

289

290 **3.2 PrV-specific systemic and mucosal humoral responses induced after IN inoculation** 291 **of the PLGA-PEI-nanovectored DNA vaccine encoding PrV-gB (pig experiment #2)**

292 In previous studies, researchers have used nanovectors to protect DNA vaccines from
293 mucosal degradation. In the second part of this study, the PrV-gB-based DNA vaccine was
294 associated with PLGA-PEI already known to enhance DNA vaccine efficacy, mainly in mice
295 experiments.

296

297 **3.2.1 *In vitro* characterization of the nanovectored DNA plasmids**

298 The PLGA-PEI nanovectored DNA plasmids encoding luciferase were prepared as
299 described above and incubated for 72 hours with the bronchial epithelial cell line HBE-16.
300 Cytotoxic analyses performed on the supernatants of these cell cultures revealed that the
301 preparation with PLGA-PEI had no toxicity for the cells (**Fig. 4A**). Furthermore, only the
302 association of PLGA-PEI with the plasmid DNA encoding luciferase enabled the expression
303 of luciferase within the cells (**Fig. 4B**). These results indicate that the nanovectors composed
304 of PLGA-PEI are functional and can be safely administered to pigs.

305

306 **3.2.2 Determination of serum anti-PrV IgG and IgA following IN inoculation of the** 307 **PLGA-PEI-nanovectored PrV-gB-based DNA vaccine**

308 Two groups of three pigs were intranasally inoculated three times at ten-day intervals
309 with the naked PrV-gB-based DNA vaccine or PLGA-PEI PrV-gB-based DNA vaccine,
310 respectively. As a control, an additional pig was intramuscularly injected at the same time
311 points with the naked DNA vaccine. Finally, a fourth group of four non-inoculated pigs was
312 added. No adverse reactions following any of the inoculations were observed throughout the
313 pig experiment. Humoral immune responses against PrV were measured until day 50 pi (**Fig.**
314 **1B**).

315 Specific IgG and IgA titers against PrV were measured in the sera of all the pigs every
316 7-10 days throughout the pig experiment. Confirming results from experiment #1 described
317 above, anti-PrV IgG and IgA were detected in the sera of the pigs inoculated with the naked
318 DNA vaccine through the IM (**data not shown**) and IN routes (**Fig. 5A for IgG and data**
319 **not shown for IgA**). For the pigs inoculated with the PLGA-PEI-DNA vaccine, the systemic
320 anti-PrV IgG and IgA immune responses was low for all three pigs (**Fig. 5B and data not**
321 **shown, respectively**).

322

323 **3.2.3 Determination of anti-PrV sIgA in the saliva of pigs inoculated with nanovectored** 324 **pcDNA3-gB through the IN route**

325 Compared to experiment #1, saliva was collected for a longer period from day 0 until day
326 44 pi (instead of only days 29 and 37 pi as in the first pig experiment). sIgA against PrV was
327 detected in most of the pigs inoculated with the DNA vaccine after the second or third
328 inoculation (naked DNA vaccine injected through the IM route (**Fig. 6A**) or inoculated
329 through the IN route (**Fig. 6B**) and nanovectored PLGA-PEI-DNA vaccine (**Fig. 6C**)).
330 However, for the majority of the pigs, the detection of these antibodies was transient since on
331 day 44 pi, these antibodies were no longer detected (**Fig. 6A, 6B and pig #2 of Fig 6C**).

332 There was two notable exceptions: sIgA against PrV was still detected in saliva in pigs #1
333 and #3 in the PLGA-PEI DNA vaccine group on day 44 pi (titers of 3.3) (**Fig. 6C**).

334

335 **4. Discussion**

336 There is a need to develop new vaccine strategies against respiratory pathogens in pigs.
337 Very promising results for IN DNA vaccination have been obtained using mice or guinea
338 pigs (Ai et al., 2013; Du et al., 2015; Iqbal et al., 2003; Khatri et al., 2008; Nanda et al.,
339 2014). Of specific interest, IN inoculation to mice of a naked plasmid encoding the same
340 PrV-gB as the one used in the present study resulted in the induction of vaginal
341 PrV-specific sIgA, but not in protection (Yoon et al., 2008). Unfortunately, there are very
342 few data on mucosal DNA vaccination in large animals, and none on IN DNA vaccination
343 in pigs. Furthermore negative results are common. For example, a DNA vaccine against the
344 foot-and-mouth disease virus (FMDV) was not efficient in sheep when administered
345 through the IN route, regardless of whether the vaccine was naked or not (Niborski et al.,
346 2006).

347 The present study aims at generating preliminary results on the development of IN
348 DNA vaccination in pigs. To do this, we used a DNA vaccine against PrV that induces
349 immune responses after IM injection: a DNA vaccine encoding PrV gB (Dory et al., 2009;
350 Le Moigne et al., 2012). This model is especially valuable for such study because (1) the
351 virus enters the body through the nasal route (and therefore it is beneficial to generate
352 protective immunity at this entry site), and (2) it has been shown that a plasmid encoding
353 PrV-gB induced the production of mucosal sIgA against PrV in the vagina after IN
354 inoculation of mice (Yoon et al., 2008). It can thus serve as a marker of induction of
355 systemic and mucosal humoral immune responses to study new strategies to inoculate DNA
356 vaccines in pigs. At this stage, it has to be pointed out that PrV-gB alone is not able to
357 induce strong protective immunity against PrV-infection in pigs (van Rooij et al., 2000),

358 and this was also the case after IN inoculation in mice (Yoon et al., 2008). Therefore,
359 PrV-gB is fully adapted to the study we wanted to perform here since the main aim of the
360 present study was first to evaluate if IN inoculation of a DNA vaccine can induce the
361 production of immune responses, and more particularly mucosal immune responses. For
362 this reason, and because they are beyond our objective, protective studies were not
363 conducted. Before a PrV-challenge with a protective DNA vaccine encoding PrV-gB, -gC
364 and -gD (Dory et al., 2005; Gerdts et al., 1997; van Rooij et al., 2002) could be designed in
365 pigs, IN administration of DNA vaccine must first be optimized.

366 In the present study, the IM route of immunization served (1) to show that the PrV-gB
367 DNA vaccine is functional and induces the production of systemic humoral immune
368 response, and (2) to study whether sIgA against PrV are detected in the saliva of
369 intramuscularly injected pigs. In all cases, anti-PrV IgG and IgA were found in the sera of
370 these pigs; anti-PrV sIgA antibodies were detected in the saliva of 3 out of 4 pigs. To our
371 knowledge, this is the first time that such sIgA antibodies have been detected in the saliva
372 of pigs intramuscularly vaccinated with a DNA vaccine against PrV. Previously, such
373 antibodies were also detected in nasal secretions of pigs intramuscularly injected with a
374 commercial inactivated PrV vaccine (Geskytur[®]) (Le Ludec et al., 2016). Unfortunately,
375 the comparisons of the levels of antibodies obtained after the IM injection of our DNA
376 vaccine and Geskytur[®] are not possible since the sIgA levels were measured in two
377 different fluids.

378 IN inoculation of naked DNA vaccine has mainly been described as ineffective in
379 inducing immune responses or protection, with some notable exceptions. For example,
380 Svanholm *et al* reported that significant clinical protection against *Chlamydomphila*
381 *pneumonia* was obtained after IN immunization of mice with a naked plasmid encoding
382 HSP-60 (Svanholm et al., 2000). Several other studies have reported induction of specific
383 systemic (serum IgG or IgA) or mucosal (sIgA) immune responses against β -galactosidase

384 (Csaba et al., 2006; Cui and Mumper, 2002), hepatitis B virus (Khatri et al., 2008) or
385 *Streptococcus pneumoniae* (Xu et al., 2011) following IN naked DNA immunizations in
386 mice. Herein, we observed the induction of immune responses after IN inoculation of the
387 naked form of the PrV-gB DNA vaccine in pigs. This inoculation induced both systemic
388 and mucosal humoral immune responses in all the vaccinated pigs (six pigs if we take into
389 account both pig experiments). Even though the number of individuals used was too low to
390 allow significance testing, it seems that systemic anti-PrV IgG and IgA levels is lower
391 following IN inoculation than those measured in the IM group. In contrast, levels of sIgA in
392 the saliva were around the same order of magnitude in the IM and IN groups. In fact, the
393 highest levels of sIgA in the saliva were found for individuals of the IN groups in both pig
394 experiments. But we observed a high inter-individual variations, especially in the IN groups
395 that further limits our ability to interpret the data. That being said, it is noteworthy that all
396 the 6 pigs inoculated with the naked DNA vaccine induced the production of sIgA against
397 PrV in the salivary (instead of 3 out of 4 for the IM group), providing a strong evidence that
398 IN DNA vaccination induces the production of respiratory mucosal immune responses
399 against the targeted pathogen. Cao *et al* that inoculated pigs intranasally with an the
400 attenuated PrV vaccine PrV K61 measured the sIgA titers in saliva around 8 log₂ (Cao et
401 al., 2011), i.e. slightly above the results we obtained here with the naked PrV-gB-based
402 DNA vaccine, which shows that the titers that we obtained are common for the species.
403 Further studies with a higher number of individuals are now necessary to determine if the
404 IN route has a higher potency at inducing sIgA production. In addition, follow-up studies
405 will need to include a thorough optimization procedure to reduce inter-individual variations
406 and enhance the efficacy of this intranasally inoculated DNA vaccine by testing other
407 adjuvants or modifying several other parameters (use of nanovectors, ways to inoculate,
408 etc.).

409 Most researchers studying IN DNA vaccination combine their DNA vaccines with
410 nanovectors to protect the DNA molecule from mucosal environment degradation until it
411 reaches the cells involved in the development of immune responses. There are many types
412 of nanovectors (for reviews see (Bernocchi et al., 2017; Xu et al., 2014)). For our study, we
413 selected PLGA-PEI nanoparticles. Indeed, PLGA and/or PEI were previously successfully
414 used in IN DNA vaccination in mice (Du et al., 2015; Torrieri-Dramard et al., 2011).

415 In the present proof of concept study, we selected a DNA/nanovector ratio previously
416 found to be effective to transfect the bronchial lineage HBE-16 cell line *in vitro*. It did not
417 ensure success of *in vivo* IN inoculation but we assumed it would increase chances of
418 success (Ragelle et al., 2014). In association with PLGA-PEI, the duration of mucosal
419 immune response in the saliva induced by the DNA vaccine was longer for two out of three
420 pigs, compared to the three pigs inoculated intranasally with the naked DNA vaccine. This
421 result may be anecdotal, but it reveals that mucosal humoral immune responses might be
422 improved. Clearly, further studies are necessary to optimize the IN DNA vaccine to induce
423 a high and sustained mucosal immune responses. We suggest that such studies should
424 compare the efficiency of PLGA-PEI with other nanovectors, and optimize the other
425 parameters such as the DNA/nanovector ratios, total quantity of DNA, adjuvants and
426 inoculation conditions; inoculation conditions include anesthetized pigs (Janakova et al.,
427 2002) or non-anesthetized pigs (Khatri et al., 2008), the volume of vaccine, number of
428 doses, intervals between the doses, speed of inoculation, and specific devices for
429 inoculation). Only such a thorough and comprehensive approach will allow us to reliably
430 assess the protective immunity induced by IN DNA vaccine strategies.

431

432 **5. Conclusion**

433 The current study clearly showed that IN inoculation of a naked DNA vaccine encoding
434 PrV-gB induces both a systemic and a mucosal humoral immune response against PrV in

435 pigs. To the best of our knowledge, this is the first report showing the induction of immune
436 responses following IN inoculation of a naked DNA vaccine in pigs. Some immune
437 response parameters appeared enhanced when the DNA vaccine was combined to
438 PLGA-PEI nanovectors. Even though the inter-individual variability observed indicate that
439 the optimized conditions were not reached in the present study, these results suggest that it
440 is possible to improve DNA vaccine efficacy by varying its composition and inoculation
441 conditions. Based on the promising results presented herein, we encourage future studies to
442 build upon the present results and improve IN DNA vaccination in pigs.

443

444

445 **6. Funding**

446 This research was funded by the AgriFoodTransition Tremplin Carnot program (France),
447 DNAINPig research project (convention #10, 2017_00868). L.S. was the recipient of a
448 thesis salary paid by ANSES, Saint-Brieuc Armor Agglomération and Conseil
449 Départemental des Côtes d'Amor (France).

450

451 **7. Acknowledgements**

452 The authors are grateful to Dr. Mohamed Dia and Dr. Eric Pagot of ZOOPOLE
453 Development (Ploufragan, France), and to the other members of the Pig Production and
454 Experimental Unit (SPPAE) of ANSES (Ploufragan, France) for their technical help during
455 the animal experiments. They also thank Dr. Nolwenn Dheilily (Viral Genetics and Biosafety
456 Unit, ANSES, Ploufragan, France) for the review of the English of the final version of the
457 manuscript.

458

459 **8. Declaration of competing interest**

460 The authors declare that they have no known competing financial interests or personal
461 relationships that could have appeared to influence the work reported in this paper.

462

463 **References**

464 Ai, W., Yue, Y., Xiong, S., Xu, W., 2013. Enhanced protection against pulmonary
465 mycobacterial challenge by chitosan-formulated polyepitope gene vaccine is
466 associated with increased pulmonary secretory IgA and gamma-interferon(+) T cell
467 responses. *Microbiol Immunol* 57, 224-235.

468 Babic, N., Mettenleiter, T.C., Ugolini, G., Flaman, A., Coulon, P., 1994. Propagation
469 of pseudorabies virus in the nervous system of the mouse after intranasal
470 inoculation. *Virology* 204, 616-625.

471 Berchel, M., Le Gall, T., Haelters, J.P., Lehn, P., Montier, T., Jaffres, P.A., 2015.
472 Cationic lipophosphoramidates containing a hydroxylated polar headgroup for
473 improving gene delivery. *Mol Pharm* 12, 1902-1910.

474 Bernocchi, B., Carpentier, R., Betbeder, D., 2017. Nasal nanovaccines. *Int J Pharm*
475 530, 128-138.

476 Cao, D., Li, H., Jiang, Z., Cheng, Q., Yang, Z., Xu, C., Cao, G., Zhang, L., 2011. CpG
477 oligodeoxynucleotide synergizes innate defense regulator peptide for enhancing
478 the systemic and mucosal immune responses to pseudorabies attenuated virus
479 vaccine in piglets in vivo. *Int Immunopharmacol* 11, 748-754.

480 Csaba, N., Garcia-Fuentes, M., Alonso, M.J., 2009. Nanoparticles for nasal
481 vaccination. *Adv Drug Deliv Rev* 61, 140-157.

482 Csaba, N., Sanchez, A., Alonso, M.J., 2006. PLGA:poloxamer and PLGA:poloxamine
483 blend nanostructures as carriers for nasal gene delivery. *J Control Release* 113,
484 164-172.

- 485 Cui, Z., Mumper, R.J., 2002. Intranasal administration of plasmid DNA-coated
486 nanoparticles results in enhanced immune responses. *J Pharm Pharmacol* 54,
487 1195-1203.
- 488 Dalmo, R.A., 2018. DNA vaccines for fish: Review and perspectives on correlates of
489 protection. *J Fish Dis* 41, 1-9.
- 490 Dhakal, S., Renukaradhya, G.J., 2019. Nanoparticle-based vaccine development and
491 evaluation against viral infections in pigs. *Vet Res* 50, 90.
- 492 Dory, D., Remond, M., Beven, V., Cariolet, R., Backovic, M., Zientara, S., Jestin, A.,
493 2009. Pseudorabies virus glycoprotein B can be used to carry foot and mouth
494 disease antigens in DNA vaccination of pigs. *Antiviral Res* 81, 217-225.
- 495 Dory, D., Torché, A.M., Béven, V., Blanchard, P., Loizel, C., Cariolet, R., Jestin, A.,
496 2005. Effective protection of pigs against lethal Pseudorabies virus infection after a
497 single injection of low-dose Sindbis-derived plasmids encoding PrV gB, gC and gD
498 glycoproteins. *Vaccine* 23, 3483-3491.
- 499 Du, L., Li, B., Xu, X., Sun, B., Pang, F., Wen, L., Huang, K., He, K., 2015. Adsorption
500 of a porcine reproductive and respiratory syndrome virus DNA vaccine candidate
501 onto biodegradable nanoparticles improves immunogenicity in mice. *Arch Virol*
502 160, 1543-1547.
- 503 Dufour, V., 2001. DNA vaccines: new applications for veterinary medicine.
504 *Veterinary Sciences Tomorrow*, 1-20.
- 505 Eclercy, J., Renson, P., Lebret, A., Hirchaud, E., Normand, V., Andraud, M.,
506 Paboeuf, F., Blanchard, Y., Rose, N., Bourry, O., 2019. A Field Recombinant Strain
507 Derived from Two Type 1 Porcine Reproductive and Respiratory Syndrome Virus
508 (PRRSV-1) Modified Live Vaccines Shows Increased Viremia and Transmission in
509 SPF Pigs. *Viruses* 11.
- 510 Farris, E., Brown, D.M., Ramer-Tait, A.E., Pannier, A.K., 2016. Micro- and
511 nanoparticulates for DNA vaccine delivery. *Experimental biology and medicine*
512 241, 919-929.

- 513 Gerdts, V., Jöns, A., Makoschey, B., Visser, N., Mettenleiter, C., 1997. Protection of
514 pigs against Aujeszky's disease by DNA vaccination. *J. Gen. Virol.* 78, 2139-2146.
- 515 Gomes, D.C., Pinto, E.F., de Melo, L.D., Lima, W.P., Larraga, V., Lopes, U.G.,
516 Rossi-Bergmann, B., 2007. Intranasal delivery of naked DNA encoding the LACK
517 antigen leads to protective immunity against visceral leishmaniasis in mice. *Vaccine*
518 25, 2168-2172.
- 519 Hass, J., Matuszewski, S., Cieslik, D., Haase, M., 2011. The role of swine as "mixing
520 vessel" for interspecies transmission of the influenza A subtype H1N1: a
521 simultaneous Bayesian inference of phylogeny and ancestral hosts. *Infection,
522 genetics and evolution : journal of molecular epidemiology and evolutionary
523 genetics in infectious diseases* 11, 437-441.
- 524 Iqbal, M., Lin, W., Jabbal-Gill, I., Davis, S.S., Steward, M.W., Illum, L., 2003. Nasal
525 delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial
526 virus (RSV) induces protective CTL responses in BALB/c mice. *Vaccine* 21,
527 1478-1485.
- 528 Janakova, L., Bakke, H., Haugen, I.L., Berstad, A.K., Hoiby, E.A., Aaberge, I.S.,
529 Haneberg, B., 2002. Influence of intravenous anesthesia on mucosal and systemic
530 antibody responses to nasal vaccines. *Infect Immun* 70, 5479-5484.
- 531 Khatri, K., Goyal, A.K., Gupta, P.N., Mishra, N., Vyas, S.P., 2008. Plasmid DNA
532 loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
533 *Int J Pharm* 354, 235-241.
- 534 Kraehenbuhl, J.P., Neutra, M.R., 2013. Mucosal vaccines: where do we stand?
535 *Current topics in medicinal chemistry* 13, 2609-2628.
- 536 Lawson, L.B., Norton, E.B., Clements, J.D., 2011. Defending the mucosa: adjuvant
537 and carrier formulations for mucosal immunity. *Curr Opin Immunol* 23, 414-420.
- 538 Le Gall, T., Berchel, M., Le Hir, S., Fraix, A., Salaun, J.Y., Ferec, C., Lehn, P., Jaffres,
539 P.A., Montier, T., 2013. Arsonium-containing lipophosphoramides, poly-functional
540 nano-carriers for simultaneous antibacterial action and eukaryotic cell transfection.
541 *Advanced healthcare materials* 2, 1513-1524.

542 Le Luduec, J.B., Debeer, S., Piras, F., Andreoni, C., Boudet, F., Laurent, P.,
543 Kaiserlian, D., Dubois, B., 2016. Intradermal vaccination with un-adjuvanted
544 sub-unit vaccines triggers skin innate immunity and confers protective respiratory
545 immunity in domestic swine. *Vaccine* 34, 914-922.

546 Le Moigne, V., Cariolet, R., Beven, V., Keranflec'h, A., Jestin, A., Dory, D., 2012.
547 Electroporation improves the immune response induced by a DNA vaccine against
548 pseudorabies virus glycoprotein B in pigs. *Res Vet Sci* 93, 1032-1035.

549 Liebler-Tenorio, E.M., Pabst, R., 2006. MALT structure and function in farm
550 animals. *Vet Res* 37, 257-280.

551 Lindberg, M.F., Le Gall, T., Carmoy, N., Berchel, M., Hyde, S.C., Gill, D.R., Jaffres,
552 P.A., Lehn, P., Montier, T., 2015. Efficient in vivo transfection and safety profile of a
553 CpG-free and codon optimized luciferase plasmid using a cationic
554 lipophosphoramidate in a multiple intravenous administration procedure.
555 *Biomaterials* 59, 1-11.

556 Liu, P., Bai, Y., Jiang, X., Zhou, L., Yuan, S., Yao, H., Yang, H., Sun, Z., 2018. High
557 reversion potential of a cell-adapted vaccine candidate against highly pathogenic
558 porcine reproductive and respiratory syndrome. *Vet Microbiol* 227, 133-142.

559 Lycke, N., 2012. Recent progress in mucosal vaccine development: potential and
560 limitations. *Nat Rev Immunol* 12, 592-605.

561 McGhee, J.R., Fujihashi, K., 2012. Inside the mucosal immune system. *PLoS Biol* 10,
562 e1001397.

563 Nanda, R.K., Hajam, I.A., Edao, B.M., Ramya, K., Rajangam, M., Chandra Sekar, S.,
564 Ganesh, K., Bhanuprakash, V., Kishore, S., 2014. Immunological evaluation of
565 mannosylated chitosan nanoparticles based foot and mouth disease virus DNA
566 vaccine, pVAC FMDV VP1-OmpA in guinea pigs. *Biologicals* 42, 153-159.

567 Niborski, V., Li, Y., Brennan, F., Lane, M., Torche, A.M., Remond, M., Bonneau, M.,
568 Riffault, S., Stirling, C., Hutchings, G., Takamatsu, H., Barnett, P., Charley, B.,
569 Schwartz-Cornil, I., 2006. Efficacy of particle-based DNA delivery for vaccination of
570 sheep against FMDV. *Vaccine* 24, 7204-7213.

571 Oh, Y.K., Kim, J.P., Hwang, T.S., Ko, J.J., Kim, J.M., Yang, J.S., Kim, C.K., 2001. Nasal
572 absorption and biodistribution of plasmid DNA: an alternative route of DNA
573 vaccine delivery. *Vaccine* 19, 4519-4525.

574 Pabst, O., 2012. New concepts in the generation and functions of IgA. *Nat Rev*
575 *Immunol* 12, 821-832.

576 Pavot, V., Rochereau, N., Genin, C., Verrier, B., Paul, S., 2012. New insights in
577 mucosal vaccine development. *Vaccine* 30, 142-154.

578 Ragelle, H., Riva, R., Vandermeulen, G., Naeye, B., Pourcelle, V., Le Duff, C.S.,
579 D'Haese, C., Nysten, B., Braeckmans, K., De Smedt, S.C., Jerome, C., Preat, V., 2014.
580 Chitosan nanoparticles for siRNA delivery: optimizing formulation to increase
581 stability and efficiency. *J Control Release* 176, 54-63.

582 Shau, M.D., Shih, M.F., Lin, C.C., Chuang, I.C., Hung, W.C., Hennink, W.E.,
583 Cherng, J.Y., 2012. A one-step process in preparation of cationic nanoparticles with
584 poly(lactide-co-glycolide)-containing polyethylenimine gives efficient gene
585 delivery. *Eur J Pharm Sci* 46, 522-529.

586 Somasundaram, C., Takamatsu, H., Andréoni, C., Audonnet, J.-C., Fisher, L.,
587 Lefèvre, F., Charley, B., 1999. Enhanced protective response and immuno-adjuvant
588 effects of porcine GM-CSF on DNA vaccination of pigs against Aujeszky's disease
589 virus. *Vet. Immunol. Immunopathol.* 70, 277-287.

590 Svanholm, C., Bandholtz, L., Castanos-Velez, E., Wigzell, H., Rottenberg, M.E.,
591 2000. Protective DNA immunization against *Chlamydia pneumoniae*. *Scand J*
592 *Immunol* 51, 345-353.

593 Torrieri-Dramard, L., Lambrecht, B., Ferreira, H.L., Van den Berg, T., Klatzmann,
594 D., Bellier, B., 2011. Intranasal DNA vaccination induces potent mucosal and
595 systemic immune responses and cross-protective immunity against influenza
596 viruses. *Mol Ther* 19, 602-611.

597 van Rooij, E.M., Glansbeek, H.L., Hilgers, L.A., te Lintelo, E.G., de Visser, Y.E.,
598 Boersma, W.J., Haagmans, B.L., Bianchi, A.T., 2002. Protective antiviral immune

599 responses to pseudorabies virus induced by DNA vaccination using
600 dimethyldioctadecylammonium bromide as an adjuvant. *J Virol* 76, 10540-10545.

601 van Rooij, E.M., Haagmans, B.L., Glansbeek, H.L., de Visser, Y.E., de Bruin, M.G.,
602 Boersma, W., Bianchi, A.T., 2000. A DNA vaccine coding for glycoprotein B of
603 pseudorabies virus induces cell-mediated immunity in pigs and reduces virus
604 excretion early after infection. *Vet Immunol Immunopathol* 74, 121-136.

605 Wang, S., Liu, H., Zhang, X., Qian, F., 2015. Intranasal and oral vaccination with
606 protein-based antigens: advantages, challenges and formulation strategies. *Protein*
607 *& cell* 6, 480-503.

608 Xu, J., Dai, W., Wang, Z., Chen, B., Li, Z., Fan, X., 2011. Intranasal vaccination with
609 chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects
610 mice against nasopharyngeal colonization by *Streptococcus pneumoniae*. *Clin*
611 *Vaccine Immunol* 18, 75-81.

612 Xu, Y., Yuen, P.W., Lam, J.K., 2014. Intranasal DNA Vaccine for Protection against
613 Respiratory Infectious Diseases: The Delivery Perspectives. *Pharmaceutics* 6,
614 378-415.

615 Yoon, H.A., Han, Y.W., Aleyas, A.G., George, J.A., Kim, S.J., Kim, H.K., Song, H.J.,
616 Cho, J.G., Eo, S.K., 2008. Protective immunity induced by systemic and mucosal
617 delivery of DNA vaccine expressing glycoprotein B of pseudorabies virus. *J*
618 *Microbiol Biotechnol* 18, 591-599.

619

620

621

622

623

624 **Figure legends:**

625

626 **Figure 1: Schematic representation of the animal immunization experiments.**

627 (A) Assessment of immune potentials in pigs inoculated intranasally with a naked PrV-gB
628 DNA vaccine. (B) Assessment of immune potentials in pigs inoculated intranasally with a
629 formulated PrV-gB DNA vaccine.

630

631 **Figure 2: ELISA determination of systemic IgG antibody levels against PrV after**
632 **inoculation with a naked PrV-gB-based DNA vaccine.**

633 Pigs were inoculated three times with a naked pcDNA3-gB DNA vaccine, as indicated by
634 the arrows. Pig sera were collected every 8-10 days throughout the pig experiment. IgG
635 titers of the two non-inoculated pigs and the three pigs inoculated by the IM route are
636 indicated in (A). IgG titers of the three pigs inoculated by the IN route are indicated in (B).
637 Dilutions were performed in triplicate and the threshold of positivity was established as the
638 OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales.
639 Arrows topped with a number indicate the inoculations with DNA vaccine.

640

641 **Figure 3: ELISA determination of salivary sIgA antibody levels against PrV after**
642 **inoculation with a naked PrV-gB-based DNA vaccine.**

643 Pigs were inoculated three times with the DNA vaccine at ten-day intervals. Pig saliva
644 samples were collected at days 29 and 37 after the first inoculation (dpi). Black bars
645 correspond to 29 dpi and dashed bars to 37 dpi. Saliva dilutions were performed in triplicate
646 and the threshold of positivity was established as the OD mean of the negative controls \pm 3
647 SD. Antibody titers are presented in log₂ scales.

648

649 **Figure 4: *In vitro* toxicity and cell transfection potentials of naked and PLGA-PEI**
650 **associated plasmids.**

651 HBE-16 cells were incubated with 1 µg of naked plasmid pTG11033 (Naked DNA), 1 µg
652 of plasmid DNA pTG11033 adsorbed onto premade PLGA-PEI nanoparticles at a weight to
653 weight ratio of 12 (PLGA-PEI-DNA). Cell viabilities (**A**) and luciferase expressions (**B**)
654 were measured at 72 hours post-transfection. The untransfected cell condition served as a
655 reference level (NT cells) corresponding to 100% viability (dashed line) (A) or to luciferase
656 base level (B). In the latter case, the values expressed in relative light units (RLUs) per
657 protein mg measured in the cell lysates are indicated. Mean results of three independent
658 experiments are presented ± SD. Significant differences between each condition and their
659 respective controls were determined with the non-parametric Mann–Whitney test (ab, $p <$
660 0.05).

661

662 **Figure 5: ELISA determination of systemic IgG antibody levels against PrV after**
663 **intranasal inoculation with a naked or PLGA-PEI associated PrV-gB-based DNA**
664 **vaccine.**

665 Pigs were inoculated three times with the DNA vaccine as indicated by the arrows. Pig sera
666 were collected every 8-10 days throughout the pig experiment. Results for the three pigs
667 inoculated with naked pcDNA3-gB are indicated in (**A**). Results for the three pigs inoculated
668 with PLGA-PEI-pcDNA3-gB are indicated in (**B**). Dilutions were performed in triplicate and
669 the threshold of positivity was established as the OD mean of the negative controls ± 3 SD.
670 Antibody titers are presented in log₂ scales. Arrows topped with a number indicate the
671 inoculations with DNA vaccine.

672

673 **Figure 6: ELISA determination of salivary sIgA antibody levels against PrV after**
674 **inoculation with a naked or PLGA-PEI associated PrV-gB based DNA vaccine.**

675 Pigs were inoculated three times with the DNA vaccine as indicated by the arrows. Pig
676 saliva samples were collected every 8-10 days throughout the pig experiment. Results for
677 the four non-inoculated pigs and the single animal inoculated through the IM route are
678 indicated in **(A)**. Results for the three pigs inoculated by the IN route with naked
679 pcDNA3-gB are indicated in **(B)**. Results for the three pigs inoculated by the IN route with
680 PLGA-PEI-pcDNA3-gB are indicated in **(C)**. Dilutions were performed in triplicate and the
681 threshold of positivity was established as the OD mean of the negative controls \pm 3 SD.
682 Antibody titers are presented in log₂ scales. Arrows topped with a number indicate the
683 inoculations with DNA vaccine.

684




Figure 1: Schematic representation of the animal immunization experiments.

(A) Assessment of immune potentials in pigs inoculated intranasally with a naked PrV-gB DNA vaccine. **(B)** Assessment of immune potentials in pigs inoculated intranasally with a formulated PrV-gB DNA vaccine.




Figure 2: ELISA determination of systemic IgG antibody levels against PrV after inoculation with a naked PrV-gB-based DNA vaccine.

Pigs were inoculated three times with a naked pcDNA3-gB DNA vaccine, as indicated by the arrows. Pig sera were collected every 8-10 days throughout the pig experiment. IgG titers of the two non-inoculated pigs and the three pigs inoculated by the IM route are indicated in **(A)**. IgG titers of the three pigs inoculated by the IN route are indicated in **(B)**. Dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales. Arrows topped with a number indicate the inoculations with DNA vaccine.




Figure 3: ELISA determination of salivary sIgA antibody levels against PrV after inoculation with a naked PrV-gB-based DNA vaccine.

Pigs were inoculated three times with the DNA vaccine at ten-day intervals. Pig saliva samples were collected at days 29 and 37 after the first inoculation (dpi). Black bars correspond to 29 dpi and dashed bars to 37 dpi. Saliva dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales.





Figure 4: *In vitro* toxicity and cell transfection potentials of naked and PLGA-PEI associated plasmids.

HBE-16 cells were incubated with 1 μg of naked plasmid pTG11033 (Naked DNA), 1 μg of plasmid DNA pTG11033 adsorbed onto premade PLGA-PEI nanoparticles at a weight to weight ratio of 12 (PLGA-PEI-DNA). Cell viabilities (**A**) and luciferase expressions (**B**) were measured at 72 hours post-transfection. The untransfected cell condition served as a reference level (NT cells) corresponding to 100% viability (dashed line) (**A**) or to luciferase base level (**B**). In the latter case, the values expressed in relative light units (RLUs) per protein mg measured in the cell lysates are indicated. Mean results of three independent experiments are presented \pm SD. Significant differences between each condition and their respective controls were determined with the non-parametric Mann–Whitney test (ab, $p < 0.05$).

A



B




Figure 5: ELISA determination of systemic IgG antibody levels against PrV after intranasal inoculation with a naked or PLGA-PEI associated PrV-gB-based DNA vaccine.

Pigs were inoculated three times with the DNA vaccine as indicated by the arrows. Pig sera were collected every 8-10 days throughout the pig experiment. Results for the three pigs inoculated with naked pcDNA3-gB are indicated in **(A)**. Results for the three pigs inoculated with PLGA-PEI-pcDNA3-gB are indicated in **(B)**. Dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales. Arrows topped with a number indicate the inoculations with DNA vaccine.




Figure 6: ELISA determination of salivary sIgA antibody levels against PrV after inoculation with a naked or PLGA-PEI associated PrV-gB based DNA vaccine.

Pigs were inoculated three times with the DNA vaccine as indicated by the arrows. Pig saliva samples were collected every 8-10 days throughout the pig experiment. Results for the four non-inoculated pigs and the single animal inoculated through the IM route are indicated in **(A)**. Results for the three pigs inoculated by the IN route with naked pcDNA3-gB are indicated in **(B)**. Results for the three pigs inoculated by the IN route with PLGA-PEI-pcDNA3-gB are indicated in **(C)**. Dilutions were performed in triplicate and the threshold of positivity was established as the OD mean of the negative controls \pm 3 SD. Antibody titers are presented in log₂ scales. Arrows topped with a number indicate the inoculations with DNA vaccine.